Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis
ICD-10 N03.3 is a billable code used to indicate a diagnosis of chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis.
Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis is characterized by persistent inflammation of the glomeruli, leading to a gradual decline in renal function. This condition is often associated with significant proteinuria, hematuria, and hypertension. The diffuse mesangial proliferation indicates an increase in mesangial cells and matrix, which can be identified through renal biopsy. Patients may present with symptoms such as edema, fatigue, and decreased urine output. The underlying pathophysiology involves immune-mediated damage to the glomeruli, often linked to systemic diseases such as lupus or infections. Management typically includes controlling blood pressure, reducing proteinuria with ACE inhibitors or ARBs, and addressing any underlying conditions. Regular monitoring of renal function and laboratory parameters is essential to assess disease progression and treatment efficacy.
Detailed renal function tests, biopsy results, and treatment plans.
Patients presenting with chronic kidney disease, hypertension, and proteinuria.
Ensure all lab results and clinical findings are documented to support the diagnosis.
Comprehensive patient history, physical examination findings, and management strategies.
Management of patients with chronic kidney disease and comorbid conditions.
Coordination with nephrology for shared care of complex cases.
When a renal biopsy is performed to confirm the diagnosis of diffuse mesangial proliferative glomerulonephritis.
Document indication for biopsy, consent, and pathology results.
Nephrology specialists should ensure thorough documentation of the biopsy findings.
Common symptoms include edema, hypertension, proteinuria, hematuria, and fatigue. Patients may also experience decreased urine output.
Diagnosis typically involves a combination of clinical evaluation, laboratory tests showing proteinuria and hematuria, and renal biopsy to confirm the presence of mesangial proliferation.
